Clicky

Alkermes plc(ALKS)

Description: Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA/ FAMPYRA for the treatment of multiple sclerosis; BYDUREON for the treatment of type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for severe pain; EMEND for the treatment of nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES for the treatment of cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE for the prevention of renal transplant rejection; NAPRELAN for various mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFE Ditab CR for hypertension; and DILZEM SR, DILZEM XL, DILTELAN, ACALIX CD, DINISOR, TILAZEM CR, and CARDIZEM CD for hypertension and/or angina. In addition, it develops ALKS 9070, which is in phase 3 study for the treatment of schizophrenia; ALKS 37 that is under phase 2b study for the treatment of opioid-induced constipation; ALKS 33, which has completed phase 2 study for modulation of brain opioid receptors; ALKS 5461 that is under phase 2 study for the treatment of depressive disorder, as well as under phase 1b study for the treatment of cocaine dependence; and ZOHYDRO for pain relief. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration with Janssen Pharmaceutica N.V. for the development of RISPERDAL CONSTA. The company was founded in 1987 and is headquartered in Dublin, Ireland.


Keywords: Biopharmaceutical Pain Diabetes Surgery Chemotherapy Alcohol Hypertension Multiple Sclerosis Organic Chemistry Schizophrenia Opioids Lipid Cholesterol Neurochemistry Spas Nausea Constipation Morphinans Angina Depressive Disorder Hyperactivity Disorder I Diabetes Treatment Of Multiple Sclerosis Pharmaceutical Wholesalers Cocaine Ii Diabetes Obsessive Compulsive Disorder Transplant Rejection Treatment Of Schizophrenia Cachexia Opioid Antagonists Opioid Induced Constipation Atypical Antipsychotics Opioid Receptors Spasticity Luvox Cr Paliperidone Renal Transplant Zanaflex

Home Page: www.alkermes.com

ALKS Technical Analysis

Connaught House
Dublin, 4
Ireland
Phone: 353 1 772 8000


Officers

Name Title
Mr. Richard F. Pops Chairman & CEO
Mr. Iain Michael Brown Sr. VP & CFO
Mr. Blair C. Jackson Exec. VP & COO
Mr. David Joseph Gaffin Exec. VP, Chief Legal Officer, Chief Compliance Officer & Sec.
Dr. Craig C. Hopkinson M.D. Exec. VP of R&D and Chief Medical Officer
Dr. Floyd E. Bloom M.D. Founder
Mr. Thomas Harvey Chief Information Officer & Sr. VP of IT
Ms. Sandra Coombs Sr. VP of Corp. Affairs & Investor Relations
Mr. Michael J. Landine Sr. VP of Corp. Devel. & Chief Risk Officer
Mr. Stephen Schiavo Sr. VP of HR

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 588.2353
Trailing PE: 0
Price-to-Book MRQ: 4.0367
Price-to-Sales TTM: 3.6432
IPO Date: 1991-07-16
Fiscal Year End: December
Full Time Employees: 2211
Back to stocks